Shilpa Medicare Limited announced that the US FDA has accepted the New Drug Application for Oxylanthanum Carbonate (OLC) filed by its partner Unicycive, targeting a decision by June 28, 2025, which may enhance treatment for kidney disease patients. Shilpa will supply the product commercially if approved, expected to launch in late 2025.